{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-305418","form_type":"8-K","ticker":"ENGN","cik":"0001980845","company_name":"enGene Therapeutics Inc.","filed_at":"2026-07-16T12:06:47+00:00","discovered_at":"2026-07-16T12:10:00.570810+00:00","generated_at":"2026-07-16T12:10:05.824029+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"enGene chairman Glickman resigns; Heffernan appointed chair; BLA submission planned for 2H 2026","bullets":["Dr. Richard Glickman resigned as director and chairman effective July 15, 2026; no disagreement.","Michael Heffernan appointed as chairman; he has over 30 years biopharma experience.","Pre-BLA meeting with FDA and BLA submission for detalimogene planned for 2H 2026.","Potential FDA approval of detalimogene in 2027.","Detalimogene is being evaluated in Phase 2 LEGEND trial for high-risk NMIBC."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-305418","json":"https://secwatch.observer/filing/0001193125-26-305418.json","markdown":"https://secwatch.observer/filing/0001193125-26-305418.md","text":"https://secwatch.observer/filing/0001193125-26-305418.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1980845/000119312526305418/0001193125-26-305418-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1980845/000119312526305418/engn-20260715.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-16T12:10:05.824029+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}